The Celgene and GV-backed cancer and atopic dermatitis drug developer is now targeting $75m in an initial public offering it postponed in August.
US-based small molecule therapy developer Rapt Therapeutics, which counts pharmaceutical company Celgene and internet technology group Alphabet as investors, has resubmitted plans to go public with a $75m target.
The company initially filed in July this year to raise up to $86.3m in an initial public offering, and set a range that would have netted it $70m to $80m two weeks later. It announced the following month it was postponing the offering but never formally withdrew.
The planned offering…
